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CObjectives: To evaluate the cost-effectiveness of bendamustine com-
pared with chlorambucil as first-line treatment for patients with
chronic lymphocytic leukemiawhowould be considered unsuitable for
treatment with fludarabine combination chemotherapy regimens.
Methods: A semi-Markov approach was used to estimate time in each
health state. The model was parameterized primarily by using data
from a phase III randomized, open-label trial comparing bendamustine
with chlorambucil. It captured the increased progression-free survival
and improved response rates with bendamustine, and the cost and
quality of life impacts of postprogression treatments. The analysis was
conducted from the perspective of the National Health Service in Eng-
land andWales. A lifetime (35-year) time horizon was used. Determin-
istic sensitivity analyses, probabilistic sensitivity analyses, and sub-
group analyses in older patients and patients with poor performance
status were carried out. Results: The estimated incremental cost-ef-
fectiveness ratiowas £11,960 per quality-adjusted life-year. None of the O
rnati
al So
http://dx.doi.org/10.1016/j.jval.2012.03.1389eterministic sensitivity analyses increased the incremental cost-ef-
ectiveness ratio by more than £2000. Subgroup analyses showed that
endamustine remained cost-effective across different patient groups.
robabilistic sensitivity analysis showed that at the £20,000 threshold,
endamustine has a 90% probability of being cost-effective.
onclusions: Bendamustine represents good value for first-line treat-
ent of patients with chronic lymphocytic leukemia who are unsuit-
ble for treatment with fludarabine combination chemotherapy. The
ncremental cost-effectiveness ratio is below the thresholds commonly
pplied in England and Wales (£20,000–£30,000 per quality-adjusted
ife-year).
eywords: bendamustine, chlorambucil, chronic lymphocytic leuk-
mia, cost-effectiveness, cost-utility, QALY.
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utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Chronic lymphocytic leukemia (CLL) is the most common leuke-
mia among adults in industrialized countries [1]. In 2008, the inci-
dence of CLL in the United Kingdom (UK) was 3.3 per 100,000 and
2798 new cases were diagnosed [2]. The risk of developing CLL
ncreases with age, and it accounts for 40% of all leukemia cases in
hose aged older than 65 years [3]. The median age at diagnosis is
between 65 and 70 years [3].
Formost patients, CLL is incurable, and follows a relapsing and
remitting course. It is estimated that around one third of patients
will be asymptomatic and never require treatment. The subset of
patients who do need treatment is heterogeneous in terms of age,
comorbidities, and performance status, and clinicians have to de-
cide whether to adopt a “palliative” approach (treat symptomatic
disease with regimens causing minimal treatment-related toxic-
ity) or to aim for improved progression-free survival (PFS) and re-
sponse rates, and, hopefully, longer overall survival.
CLL is typically responsive to several courses of chemother-
apy, although the depth of response tends to decrease with each
subsequent line of therapy. There is a gradual onset of extensive
* Address correspondence to: William Dunlop, Mundipharma Inte
0GW, UK.
E-mail: will.dunlop@mundipharma.co.uk.
1098-3015/$36.00 – see front matter Copyright © 2012, Internation
Published by Elsevier Inc.bone marrow infiltration, bulky disease, and recurrent infec-
tion. Eventually, the disease may transform into a localized
high-grade lymphoma (Richter’s transformation) or into
prolymphocytic leukemia.
Fludarabine plus cyclophosphamide and rituximab is consid-
ered the “gold standard” first-line treatment in the UK [4] and is
therefore usedwhen clinicians decide to aim for improved PFS and
response rates. Discussions, however, with a group of leading he-
matologists have suggested that the toxicity profile of fludarabine
(particularly immunosuppression due to long-term T-cell toxicity)
makes it unsuitable for around 50% of patients (generally those
aged older than 65 yearswith comorbidities and poor performance
status). These patients are treated with chlorambucil, which is
generally well tolerated but has relatively poor efficacy compared
with fludarabine combination chemotherapy regimens in terms of
the depth of remission [5]. Chlorambucil therefore tends to be used
when clinicians decide to take a palliative approach.
Bendamustine is licensed in the UK for first-line treatment of
CLL (Binet stage B or C) in patients for whom fludarabine combi-
nation chemotherapy is not appropriate. It therefore offers an al-
ternative for patients who would traditionally receive chloram-
onal Limited, Cambridge Science Park, Milton Rd, Cambridge CB4
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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bendamustine offers substantial benefits over chlorambucil for
patients with previously untreated CLL [6]. The overall response
rate (ORR, i.e., the proportion of patients achieving either a com-
plete or partial response to treatment) was significantly higher
with bendamustine than with chlorambucil (68% vs. 31%; P 
.0001). More patients achieved a complete response (CR) with
endamustine than with chlorambucil (31% vs. 2%; P  0.0001).
Median PFS (i.e., time from randomization to first progression, or
relapse after remission, or death) was significantly longer with
bendamustine than with chlorambucil (21.6 months vs. 8.3
months; P  0.0001). The overall survival curves also showed a
clear divergence in favor of bendamustine, although no statisti-
cally significant difference was observed.
Guidance issued by the UK’s National Institute for Health and
Clinical Excellence (NICE) in February 2011 recommended benda-
mustine for use within the National Health Service (NHS) in Eng-
land and Wales [7]. The cost-utility analysis described below was
carried out to inform the appraisal of bendamustine by NICE.
Based on the clinical data described above and data from the lit-
erature, it was designed to evaluate first-line bendamustine com-
pared with chlorambucil in patients whowould be considered un-
suitable for fludarabine combination chemotherapy regimens.
Methods
Model structure
A semi-Markov approach was used to estimate time in each health
state. Parametric survival analyses of the overall survival end point
were used directly to estimate the probability of death in each cycle.
Probabilities of transitioning betweenhealth states conditional upon
being alive were then applied to estimate the spread of patients
50% o
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Fig. 1 – Model structure. Adverse events were modeled sepa
survival.across these health states over time. This approach allowed time in
state to influence the probability of progression from each first-line
response state and the choice to re-treat or switch to second-line
treatment following progression. This enabled more accurate mod-
eling of the cost and quality of life implications of these early transi-
tions (onwhichwehad themost information). Costs and health out-
comes were simulated over a patient’s lifetime (35 years). The
analysis was conducted from the perspective of the NHS in England
and Wales. The cost year for the study was 2009. In line with NICE
recommendations [8], the model applied a discount rate of 3.5% per
annum to costs and health outcomes. The model was programmed
in Microsoft Excel (Microsoft Corporation, Redmond, WA), and all
statistical analyses were conducted in SAS (SAS Institute, Cary, NC).
The cycle length was 3 months, and a half-cycle correction was
applied.
Figure 1 shows the model structure. All patients started treat-
ment (with bendamustine or chlorambucil) in the stable disease
(SD) health state. In the next cycle, they were allocated to their
best overall response state: SD, progressive disease (PD), partial
response (PR), or CR. Patients who entered the SD, CR, and PR
disease states then faced a probability of progressing. Patients
who progressed 12 or more months after receiving chlorambucil
were re-treated ad infinitum. In line with advice from UK clinical
experts, all other patients with PD faced a 50% probability of initi-
ating the next line of treatment (fludarabine plus cyclophospha-
mide [FC]) or entering the best supportive care (BSC) health state.
Patients receiving FC faced the possibility of response and subse-
quent progression to BSC. Patients remained in the BSC health
state until death. Having FC as a second-line therapy might seem
counterintuitive, given that bendamustine is licensed for patients
who are not suitable for treatment with fludarabine combination
chemotherapy. Consultation with UK clinical experts, however,
confirmed that some patients would be expected to receive flu-
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761V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 7 5 9 – 7 7 0darabine at second-line therapy: those who are judged to be
healthier after relapse than when they started first-line therapy
and those for whom no other options are appropriate. The model
also included the differential adverse event profiles associated
with bendamustine, chlorambucil, and FC.
Model inputs
Full systematic searches and literature reviews were carried out
for major model inputs, including randomized controlled trial
(RCT) data for bendamustine, CLL utility data, CLL resource-use
data, and data describing the efficacy of subsequent therapies.
Appropriate, recognized databases were used, including Embase,
Medline, Medline In-Process, The Cochrane Central Register of
Controlled Trials, EconLIT (using the OVID search platform), and
theNHS Economic Evaluation Database. Full details of the system-
atic searches and literature reviews can be found in the submis-
sion made to NICE [9].
Clinical data
The analysis was based on data from an open-label, phase III, RCT
by Knauf et al. [6]. The systematic review conducted to inform the
ICE appraisal identified this as the only RCT comparing benda-
ustine treatment with any comparator in CLL [9]. The study in-
cluded 319 patients with previously untreated Binet stage B or C
CLL who were randomized to treatment with bendamustine (100
mg/m2/d intravenously over 30 minutes on days 1 and 2 of a 28-
ay treatment cycle; n 162) or oral chlorambucil (0.8mg/kg orally
n days 1 and 15 of a 28-day treatment cycle; n 157). The dose of
chlorambucil was calculated by using Broca’s normalized weight
(the patient’s height in centimeters minus 100) and could be given
as divided doses on day 1/2 and day 15/16 of each cycle if neces-
sary. The primary outcomes were ORR and PFS. Responses were
assessed after three cycles and at the end of treatment. After the
last treatment cycle, patients were monitored for response and
survival every 3 months. The response evaluation was based on
the National Cancer Institute–Sponsored Working Group on CLL
criteria [10,11]. The investigators’ assessments of patients’ re-
sponses were checked by an independent committee for response
assessment;members of the independent committee for response
assessment were blinded to treatment. Secondary end points in-
cluded overall survival and quality of life. Patients’ median (range)
age was 63 (45–77) years in the bendamustine group and 66 (35–78)
years in the chlorambucil group. More than 70% of the patients in
each group had Binet stage B disease.
Transition probabilities
Table 1 shows the response rates applied in the model. Note that
he percentage of patients in each response category differs from
hat published by Knauf et al. [6]. This is because those patients
ho had no examination data (14 in the bendamustine group and
Table 1 – Best overall response to first-line treatment.
Treatment type Stable disease
(SD  unconfirmed response)
Bendamustine* (n  148)
n 23 (19  4)
% 16
Chlorambucil* (n  138)
n 37 (32  5)
% 27
nPR, nodular partial response.
* Patients who were not evaluated for response are excluded from tgroup).19 in the chlorambucil group) were included as nonresponders in
the clinical analysis but were completely excluded from the eco-
nomic analysis.
Table 2 shows the results of fitting parametric survival curves
to the time to progression (TTP), time to re-treatment, and overall
survival data. To improve the fit to the empirical data, each anal-
ysis included a treatment covariate, regardless of statistical signif-
icance. For the TTP and overall survival analyses, exponential,
Weibull, log-normal, and log-logistic parametric functions were
fitted. The preferred model was selected on the basis of visual
comparison of the Kaplan-Meier and fitted survival curves, and
using Akaike’s Information Criteria (AIC;   3) as a measure of
statistical goodness of fit [12]. Separate TTP curves were fitted for
patients with CR, PR, and SD to reflect the increased durability of
deeper remissions. For TTP in patients with CR and PR, and for
overall survival, conclusions drawn from the visual comparison of
the fitted and empirical survival curves and the AIC concurred. For
SD, the model with the lowest AIC (the Weibull) predicted a larger
difference between treatments (in favor of bendamustine) and
seemed to be heavily influenced by the tail of the bendamustine
curve. To be conservative, the log-logistic, which appeared to pro-
vide the best fit by visual inspection, was therefore used. Sensitiv-
ity analyses are presented using alternative parametric models;
the AIC statistics and all fitted curves are given in Appendix S1
in Supplemental Materials found at http://dx.doi.org/10.1016/
j.jval.2012.03.1389.
Figure 2 shows a comparison of the empirical and fitted sur-
vival curves for TTP. Figure 3 shows the same comparison for over-
all survival. For time from progression to re-treatment, an expo-
nential model was forced, as inclusion of a time-dependent
probability of re-treatment would have greatly increased the com-
plexity of themodel. As shown in Figure 4, however, this provided
a reasonable approximation to the observed data.
All analyses were conducted on the intent-to-treat (ITT) pop-
ulation from Knauf et al. [6] with patients not evaluable for
response excluded (10% of the ITT population). The analysis of
time from progression until next treatment also excluded pa-
tients who received an additional line of therapy prior to pro-
gression.
The parametric survival analyses of TTP counted progression
only as an event, with death without progression considered as
censoring. The probability of progressing in a given cycle was
therefore calculated as the probability of remaining alive multi-
plied by the probability of progression calculated from the TTP
curve. This appropriately accounts for the competing risk nature
of the progression and death end points [13]. The same approach
was applied to time to next treatment.
The ORR associated with chlorambucil re-treatment was esti-
mated by scaling the first-line ORR by using data from Robak et al.
[14]. In this study, 19 of the 103 patients who received first-line treat-
ment were re-treated. Re-treatment was associated with an odds
Partial
response (PR)
Complete response
(CR  nPR)
Progressive
disease (PD)
43 67 (50  17) 15
29 45 10
41 7 (3  4) 53
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762 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 7 5 9 – 7 7 0ratio for overall response of 0.70 (95% confidence interval 0.26–1.86)
comparedwith first-line treatment. The ratio of CR to PR andof SD to
PDpatients among those re-treatedwas assumed to be equal to first-
line treatment. Ahazard ratio (HR) comparing first-linewith re-treat-
ment PFS (17months [n 103] and 12months [n 19], respectively)
was derived assuming constant hazards. This was again used to
scale the first-line estimate for chlorambucil TTP. Because TTP was
not available by response category, response-specific progression
probabilities were estimated by using HRs comparing TTP across re-
sponse categories from Knauf et al. [6] (HR, 95% confidence interval:
CRvs. SD 0.11, 0.05–0.23; PRvs. SD 0.29, 0.14–0.58) andbyassum-
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Fig. 2 – Comparison of modeled and empirical time-to-
progression data. (A) Complete responders, (B) partial
responders, and (C) patients with stable disease.ing constant hazards.
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763V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 7 5 9 – 7 7 0Response rates for FCwere estimated from 276 patients receiv-
ing second-line FC as part of an RCT (Robak et al. [15]). This study
estimated that the proportions of patients with a best overall re-
sponse of CR, PR, SD, or PD are 15%, 53%, 26% and 6%, respectively.
It also estimated that PFS is 20.6 months for all patients (n  236)
and 27.7 months for responders (n 160). Response-specific prob-
abilities of progression were estimated by using these data, the
data comparing TTP between CR and PR patients fromKnauf et al.,
and by assuming constant hazards.
Utility values
Table 3 shows the utility values used in the model. For the treat-
ment period, utility was estimated by mapping European Organi-
sation for Research and Treatment of Cancer C30 quality of life
data (collected by Knauf et al.) to EuroQol five-dimensional ques-
tionnaire utilities by using a mapping algorithm developed by
McKenzie and van der Pol [17]. This algorithm uses data from 199
atients with inoperable esophageal cancer and has been found to
redict reasonably well for patients with utilities greater than 0.50
18], who are thought to comprisemost of our target patient group.
baseline value that was independent of treatment was calcu-
ated from 242 patients with baseline data. Data were pooled be-
ween the two treatment groups because therewas no statistically
ignificant treatment difference in overall quality of life during the
reatment period; the resulting estimate can be thought to repre-
ent the SD state. After the treatment period, utility increments or
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Fig. 3 – Comparison of modeled and empirical overall
survival data. (A) Within trial period and (B) long-term
extrapolation.ecrements relative to “no change” were estimated from a vi-gnette study by Beusterien et al. [16] and applied to the baseline
value to reflect response level and treatment line.
The model captured the quality of life impact of the following
adverse events: grade 1 to 2 nausea, nausea with vomiting, and
diarrhea; grade 3 to 4 anemia, pyrexia, and pneumonia. Utility
decrementswere applied for the duration of the cycle. For patients
who experienced these events, it was assumed that they occurred
during every treatment cycle, with the exception of pyrexia and
pneumonia, which were assumed to be experienced only once.
Costs
Table 4 shows the costs associated with treatment with benda-
mustine, chlorambucil, and FC (which was included as a subse-
quent line of therapy in the model). Doses and number of cycles
were taken fromKnauf et al. [6], Catovsky et al. [5], and Robak et al.
[15]. Treatment costs for chlorambucil were assumed to be equiv-
alent for first-line and re-treatment. It was also assumed that all
patients receiving bendamustine and FCwould receive prophylac-
tic antiemetics.
Resource use for health states and adverse eventswere derived
from an advisory board conducted in January 2010with five hema-
tologists who work in the UK NHS and are experienced in treating
CLL. The advisory boardmembers were paid for their professional
service in accordance with the Association of the British Pharma-
ceutical Industry guidelines. Patients in all health states were as-
sumed to have regular appointments with their hematologist and
regular monitoring (full blood cell count and routine biochemis-
try). These resources are incurred each month for patients in the
SDhealth state, every 3months for those in the PR state, and every
6 months for those in the CR state. Patients in the PD/BSC state
were assumed to incur these resources every 3 weeks and also
receive a blood transfusion (two units of red blood cells). The re-
sulting costs per 3-month cycle are £405 for SD, £135 for PR, £68 for
CR, and £1924 for PD/BSC.
Unit costs were from the British National Formulary 59 [19],
NHS reference costs 2008-9 [20], and the NHS Blood and Trans-
plant Annual Review 2008-2009 [22]. Table 5 shows the unit costs
used. Table 6 shows the costs associated with adverse events.
Sensitivity analyses
Sensitivity analyses were carried out on the following parameters:
first-line response rates, treatment effect covariates in survival anal-
yses, re-treatment algorithm and efficacy, FC efficacy, patient
weight, health state costs, cost of FC, adverse event costs, utility data
sources, time until quality of life benefit of treatment emerges, ad-
verse event disutility, discount rates, and time horizon.
To test the cost-effectiveness of bendamustine across a heter-
ogeneous patient group, the model analyzed the following three
subgroups: age 65 years or more, World Health Organization per-
P
ro
po
rti
on
 o
f p
at
ie
nt
s 
no
t y
et
 
re
ce
iv
in
g 
se
co
nd
-li
ne
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
0 1 2 3 4 5
Empirical chlorambucil
Empirical bendamustine
Censored observation
Fitted chlorambucil
Fitted bendamustine
Time in years from progression
Fig. 4 – Comparison of modeled and empirical time to next
treatment data.
b
a
a
h
a
p
1
764 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 7 5 9 – 7 7 0formance status 1 ormore, age 65 years ormore plusWorld Health
Organization performance status 1 or more. To simulate long-
term costs and health outcomes in these subgroups, the model
required two alterations. First, the distributions of patients across
response categories for the relevant subgroup were obtained; sec-
ond, a dummy covariable for the subgroup was included in all
survival analyses. All survival analyses used the parametric dis-
tributions from the base-case.
Probabilistic sensitivity analysis was also carried out. Distribu-
tions were assigned to each parameter subject to sampling uncer-
tainty (all parameters other than unit costs), and 5000 random
drawswere used to propagate this uncertainty through themodel.
The following distributions were used to model uncertainty
around first-line treatment outcomes: Dirichlet for the distribu-
tion of patients across best overall response levels (CR/PR/SD/PD)
and multivariate normal for parameters of parametric survival
distributions (TTP, overall survival, and time to re-treatment
outcomes).
The Dirichlet distribution was also used to represent uncer-
tainty around best response to FC (CR/PR/nonresponder). Median
TTPs following re-treatment or second-line treatment were de-
rived by assigning a beta distribution to the proportion of patients
alive at the median time point.
Ratio statistics (odds ratio for response to chlorambucil in re-
treated vs. treatment-naïve patients; HRs comparing TTP across
response categories used to inform re-treatment and second-line
TTP) were assigned log-normal distributions.
Uncertainty around the proportion of patients (cycles) inwhich
adverse events were experienced was modeled using beta distri-
butions for all lines of treatment. The beta distribution was also
used to represent uncertainty in the utility estimates. Resource-
use estimates reported as proportions were assigned beta distri-
butions. Resource-use estimates reported as counts and all (non-
drug) unit costs were assigned gamma distributions. Numbers of
cycles of treatment administered were assigned normal distribu-
tions, with random draws restricted to be non-negative (because
negative draws were extremely rare, this restriction has no mate-
rial impact).
The point estimates and variance parameters reported
above were used to parameterize each distribution. In some
cases, no variance parameters were available and the following
assumptions were therefore made: where cost estimates were
taken from NHS reference costs, the lower and upper quartiles
Table 3 – Utilities applied in the model (both treatment gro
Baseline utility (used for both treatments during
active treatment [time 0–4.9 mo]; used as
baseline utility throughout model) [6]
Unadjusted utility values from Beusterien et al. [16]*
Complete response
Partial response
No change
Progressive disease
No change  1–2 nausea
No change  1–2 nausea/vomiting
No change  1–2 diarrhea
No change  3–4 anemia
No change  3–4 pyrexia
No change  3–4 pneumonia
No change  second-line treatment
* These values are recharacterized as increments from “no change” a
utility level in the model  0.70  (0.91  0.78)  0.83.reported were assumed to represent 75% confidence intervals; awhere count data were estimated from expert opinion or unit
costs taken from nonreference cost sources, standard errors
were assumed to equal half of the mean; where proportions
were taken from expert opinion, this was assumed equivalent
to a sample of 100 patients.
Results were presented as distributions of simulations on the
cost-effectiveness plane and cost-effectiveness acceptability
curves. An expected value of perfect information (EVPI) analysis
was also conducted. EVPI was estimated as the average difference
between the net benefit of the technology that offers the maxi-
mum net benefit in a given simulation and the expected net ben-
efit of the technology that maximizes net benefit on average
across all simulations. This was then multiplied by the number of
patients expected to benefit from the information. The number of
patients expected to benefit from the information in England and
Waleswas estimated as the discounted sumof a 10-year stream of
1079 incident cases per annum [9] (average for 2010–2014 used to
extrapolate for 10 years).
Results
Table 7 shows the base-case results. The deterministic incre-
mental cost-effectiveness ratio (ICER) of £11,960 per quality-
adjusted life-year (QALY) (£11,974 in the probabilistic analysis)
indicates that although bendamustine has higher acquisition
and administration costs than chlorambucil, the modeled
health benefits (i.e., increased quality of life and overall sur-
vival) are good value at conventional decision thresholds
(£20,000–£30,000 per QALY). Treatment acquisition accounts for
30% of the difference in treatment costs; routine follow-up costs
account for 59% of the difference (this is driven by patients
treated with bendamustine living for longer). The model predic-
tions provided a close fit to the empirical data with respect to
PFS and overall survival [9]. Figure 5 shows the proportion of the
endamustine QALY and life-year advantage over chlorambucil
ccrued at each point in the model time horizon. For example,
t 10 years, 58% of the QALY gain and 50% of the life-year gain
as been accrued.
Table 8 shows the results of the key deterministic sensitivity
nalyses. Results of supplementary analyses can be found in Ap-
endix S2 in Supplemental Materials found at http://dx.doi.org/
0.1016/j.jval.2012.03.1389. None of the deterministic sensitivity
.
Mean  SD 95% confidence interval
(lower, upper)
0.70  0.22 0.67, 0.73
0.91  0.11 0.88, 0.93
0.84  0.14 0.81, 0.87
0.78  0.14 0.75, 0.82
0.68  0.20 0.64, 0.72
0.73  0.17 0.69, 0.76
0.73  0.16 0.69, 0.76
0.70  0.19 0.66, 0.74
0.69  0.18 0.65, 0.72
0.67  0.17 0.63, 0.70
0.58  0.19 0.54, 0.62
0.71  0.17 0.68, 0.75
plied to the baseline utility in themodel, e.g., the complete responseups)
nd apnalyses increased the ICER by more than £2000 per QALY. Of
765V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 7 5 9 – 7 7 0particular interest are the results obtained when treatment effect
on overall survival was removed. Although the QALY advantage of
bendamustine was substantially decreased, this was offset by a
reduction in incremental costs owing to the removal of the addi-
tional cost of extending life in bendamustine patients. The net
effect of these changes on the ICER was small.
Table 4 – Treatment costs.
Items Bendamustine
Technology cost 25 mg  5  £347.26
25 mg  20  £1379.04
100 mg  5  £1379.04
100 mg/m2 body surface area
on days 1 and 2, every 4 wk
Average body surface area:
1.72 m2
Mean number of cycles:
4.9 (SE  0.13)
Mean cost of treatment (per
course, assuming full
wastage)
£4741.54
Infusion cost First infusion  £272.10
Subsequent infusions (cost per
infusion)  £226.88
Hematologist outpatient
visit
One per cycle  £130.71
Blood count One per month  £2.97
Biochemistry One per month  £1.34
Antiemetic cost per cycle 50% Maxolon* (87.5 mg/cycle) and
domperidone (70 mg/cycle) £0.2
Total £7673.00
Notes. Costs are UK sterling.
Pharmaceutical prices taken from British National Formulary 59 (excl
andmean cycles of bendamustine/chlorambucil taken from Knauf et
were not reported in Robak et al. [15]. Cost of infusions, outpatient v
2008-9 [20]. Resource use estimated by an advisory board of five UK he
reference cost codes are available from Napp Pharmaceuticals Limite
C, cyclophosphamide; F, fludarabine; FC, fludarabine plus cyclophosp
and Clinical Excellence; SE, standard error.
* Maxolon is a trade name for metoclopramide.
Table 5 – Health state costs.
Unit cost (£)
Consultant hematologist 130.71
Full blood cell count 2.97
Routine biochemistry 1.34
Blood transfusion
Administration 84.60
Blood cells (2 units) 261.46
Notes. Costs are UK sterling.
Costs taken from NHS reference costs 2008-9 [20] and NHS Blood
and Transplant Annual Review 2008-2009 [22]. NHS reference cost
codes are available from Napp Pharmaceuticals Limited’s NICE ap-
praisal manufacturer submission document [9]. Resource use esti-
mated by an advisory board of five UK hematologists.
NHS, National Health Service; NICE, National Institute for Health
and Clinical Excellence.The subgroup analysis showed bendamustine to be cost-effec-
tive across a heterogeneous patient group. In each of the sub-
groups analyzed, the ICER remained below £14,000 per QALY.
Figure 6 shows the results of the probabilistic sensitivity anal-
ysis as distributions of simulations on the cost-effectiveness plane
and as a cost-effectiveness acceptability curve. At the £20,000 per
QALY threshold, the probability of bendamustine being cost-effec-
tive is 90%. The expected value of information associated with the
decision problem is £403. Based on a 10-year stream of 1079 cases
per annum, the EVPI is estimated at £3.7 million at a willingness-
to-pay threshold of £20,000 per QALY and £0.8 million at a thresh-
old of £30,000 per QALY.
Discussion
Before the introduction of bendamustine, chlorambucil was the
preferred first-line treatment option for patients with CLL who
would be considered unsuitable for fludarabine combination che-
motherapy regimens. Clinical data have shown that patients
treated with bendamustine have significantly better response
rates and longer PFS than those treated with chlorambucil [6]. The
high CR rate achieved with bendamustine is important, because
there is evidence that CR is associated with longer PFS [28–31].
Longer PFS equates to longer time without symptoms and treat-
ment, and hence to longer time in an improved health state. This
Chlorambucil
(comparator)
FC
2 mg  25  £8.36 F: 10 mg  20  £357.49
C: 50 mg  100  £13.85
0.8 mg/kg Broca’s weight
days 1 and 15, every 4 wk
F: 25 mg/m2 3 d per cycle
C: 250 mg/m2 3 d per cycle
Broca’s weight: 68.73 Average body surface
area: 1.72 m2
Mean number of cycles:
4.9 (SE  0.14)
Mean number of cycles:
4.6 (SE  0.20)
£91.76 £1250.54
Not applicable Not applicable
One per cycle  £208.92 (cost
for oral chemotherapy
administration)
One per cycle 
£208.92 (cost for oral
chemotherapy
administration)
One per month  £2.97 One per month  £2.97
One per month  £1.34 One per month  £1.34
None—except when having
an adverse event
50% Maxolon* (87.5 mg/
cycle) and 50%
domperidone (70 mg/
cycle) £0.24
£1136.60 £2232.51
bendamustine) [19]; FC dosage taken from Robak et al. [15]; dosages
]; mean cycles of FC taken from Catovsky et al. [5] because these data
blood cell counts, and biochemistry taken from NHS reference costs
logists (antiemetic use also taken fromHerrstedt and Roila [21]). NHS
ICE appraisal manufacturer submission document [9].
de; NHS, National Health Service; NICE, National Institute for Health50%
4
uding
al. [6
isits,
mato
d’s N
hamicorrelates with improved quality of life for patients. There is also
Table 6 – Adverse event costs.
Adverse event Frequency of event Treatment Unit
cost (£)
Total units
(mg/appointments/
admission days)
Total cost per
adverse event
episode (£)Bendamustine
(n  161;
cycles  783)
Chlorambucil
(n  151;
cycles  733)
FC
(n  272)
Cytopenias—GCSF use 3% of cycles 0.3% of cycles — IV infusion
(hematologist
consultation)
130.71 1.00 817.09
GCSF (pegfilgrastim) 686.38 1.00
Cytopenias—erythropoietin
use
0.5% of cycles 0.3% of cycles — Erythropoietin 1188.61 1.00 1188.61
Nausea (grade 1 or 2) 4.4% of patients
(18.7%–14.3%)
6.6% of patients
(13.2%–6.6%)
45% of patients Metoclopramide (50%) 0.004 87.5 0.24
Domperidone (50%) 0.002 70
Nausea/vomiting (grade 1
or 2)
14.3% of patients 6.6% of patients 51% of patients Metoclopramide (50%) 0.004 87.5 0.24
Domperidone (50%) 0.002 70
Anemia (grade 3 or 4) 5.7% of cycles
(used for
costing);
2.1% of cycles
(used for
costing);
35% of patients Transfusion 346.06 1 453.12
Nurse consultation
50%
83.40 1
2.5% (used in
utility
calculations)
0% (used in
utility
calculations)
Hematologist
consultation 50%
130.71 1
Pyrexia (grade 3 or 4) 1.9% of patients 1.3% of patients 42% of patients IV antibiotics
(Tazocin*)
0.003 126,000 3076.99
Inpatient admission 2652.23 1
Pneumonia (grade 3 or 4) 1.9% of patients 0% of patients 17% of patients IV antibiotics
(Tazocin*)
0.003 126,000 2188.00
Inpatient admission 1763.24 1
Diarrhea (grade 1 or 2) 8.7% of patients 4% of patients 32% of patients Loperamide (50%) 0.018 21 0.43
Codeine (50%) 0.002 270
Notes. Costs are UK sterling. Pharmaceutical costs taken fromBritishNational Formulary 59 [19], except erythropoietin cost, whichwas taken fromWilson et al. [23]. Costs taken fromNHS reference
costs 2008-9 [20] and NHS Blood and Transplant Annual Review 2008-2009 [22].
Frequency of events with bendamustine and chlorambucil taken from the study by Knauf et al. [6]. Frequency of events with FC taken from Robak et al. [15]. NHS reference cost codes are available
from Napp Pharmaceuticals Limited’s NICE appraisal manufacturer submission document [9].
FC, fludarabine plus cyclophosphamide; GCSF, granulocyte colony-stimulating factor; IV, intravenous; NHS, National Health Service; NICE, National Institute for Health and Clinical Excellence.
* Tazocin is a trade name for piperacillin with tazobactum.
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767V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 7 5 9 – 7 7 0some evidence of a link between CR and overall survival. In an
updated analysis of the study by Knauf et al. [32], patients who
achieved a CR (regardless of whether they were treated with ben-
damustine or chlorambucil) had a significantly longer overall sur-
vival than did those who did not (median not reached vs. 75.9
months, respectively; P  0.0018). This cost-utility analysis shows
that bendamustine has an ICER below the thresholds commonly
applied in England andWales. It is therefore a cost-effective treat-
ment option (as well as a clinically effective one) for patients who
would be considered unsuitable for fludarabine combination che-
motherapy regimens.
The EVPI analysis estimates a relatively low value of further
research (£0.8–£3.7 million depending on the threshold). Given
that this represents the upper bound on the value to further re-
search, and does not take account of what would be achievable
with a feasible sample size, it seems unlikely that further research
(particularly expensive clinical research) to inform this decision
problemwould beworthwhile. Estimation of the expected value of
partial perfect information for different parameter groups, how-
ever, would be required to confirm this for other research designs.
There are currently no definitive criteria for determiningwhich
patients would be unsuitable for treatment with fludarabine com-
bination therapy. In the absence of any formal criteria, the deci-
sion about first-line treatment in the “real-world” setting is cur-
rently a matter of physician (and patient) judgment. Factors that
influence the decision include performance status, age, and co-
morbidities. Given the lack of specific criteria, the group of pa-
tients currently treated with chlorambucil in the UK is heteroge-
neous with respect to these three parameters. The model did not
exclude any patients from the study by Knauf et al. and therefore
used a population that was heterogeneous with respect to age and
performance status. In addition, the subgroup analyses confirmed
that bendamustine appears cost-effective even if the patient pop-
ulation is restricted to elderly patients (65 years old), patients
Table 7 – Base-case results.
Costs (£)
Acquisition Administration Adverse
events
Bendamustine 4,726 2,922 375
Chlorambucil 150 1,706 190
Incremental 4,576 1,216 185
Note. Costs are UK sterling.
Incremental  bendamustine – chlorambucil.
ICER, incremental cost-effectiveness ratio; LYG, life-years gained; QA
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Fig. 5 – Impact of time horizon on incremental QALYs and
life-years. LY, life-year; QALY, quality-adjusted life-year.with a low performance status (World Health Organization status
1), or patients who fulfill both these criteria. This demonstrates
that bendamustine is cost-effective across the heterogeneous pa-
tient group that is likely to receive it.
We designed the economicmodel primarily to reflect the treat-
ment pathway of CLL patients in England and Wales, and to take
into account the health benefits and costs expected for these pa-
tients. The chosen design accurately captured the differential
gains in quality of life that patients experience according to the
depth of their clinical remission, as each level of clinical remission
was associated with a different TTP curve. We based themodel on
direct randomized trial evidence comparing bendamustine with
the appropriate comparator (chlorambucil). The model included
subsequent lines of therapy to reflect a real-world treatment set-
ting, in which patients can respond to a future therapy after en-
tering a PD health state. Inclusion of time-dependent transition
probabilities, where feasible, increased the model’s accuracy. We
developed a version of the model for Scotland, which we submit-
ted to the Scottish Medicines Consortium for appraisal. The Scot-
tishMedicines Consortium’s advice document stated that the eco-
nomic case was demonstrated and that bendamustine is accepted
for use in Scotland [33].
In the study by Knauf et al., quality of life data were collected
only during the treatment period and patients were not followed
up long-term with respect to quality of life. This meant that we
could not use these data to inform the utility differences between
different health states beyond the treatment period. These post-
treatment utility differences were therefore estimated by using
vignette-based utility values, as in previous NICE appraisals and
published models [26,27]. Baseline utility in the model was esti-
mated by mapping from the European Organisation for Research
and Treatment of Cancer C30 to the EuroQol five-dimensional
questionnaire by using an algorithm developed by McKenzie and
van der Pol [17]. This algorithm was developed by using data from
a quite different patient population (inoperable esophageal can-
cer); however, its validity has been supported by analysis of a pop-
ulation of non-Hodgkin’s lymphoma patients [18]. Alternative
mapping algorithms are available [18], and use of these algorithms
may impact on themodel results, thoughwe believe this would be
unlikely to alter the ICER substantively because it would affect
both comparators.
The analyses of clinical events were based on the ITT popula-
tion from Knauf et al., with those patients not evaluated for re-
sponse excluded (to allow transitions probabilities conditional
upon response to be estimated). These patients represented 10%
of the randomized cohort: 9% in the bendamustine group and 12%
in the chlorambucil group. Comparison of the predictionsmade by
themodel and the ITT clinical results suggests that this is unlikely
to have biased themodel results substantively. For example,mod-
eled PFS for bendamustine at 12, 24, and 36months was 74%, 42%,
and 21%, respectively, whereas for the ITT Kaplan-Meier analysis,
estimates of 79%, 48%, and 31% were observed. Modeled PFS for
Total
LYG
Total
QALY
ICER
(£/QALY)
FC
atment
Routine
follow-up
Total
935 40,043 49,000 7.81 4.82 —
710 31,065 33,821 5.83 3.55 —
226 8,978 15,179 1.99 1.27 11,960
uality-adjusted life-year.trechlorambucil at the same time periods was 31%, 6%, and 1%, re-
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Variable Base-case Sensitivity analysis ICER (£)
Treatment covariate
Stable disease TTP Included Excluded 12,007
Partial response TTP Included Excluded 13,387
Complete response TTP Included Excluded 12,382
Time to re-treat Included Excluded 11,982
Overall survival Included Excluded 10,997
First-line response
Chlorambucil overall response Base-case Upper CI 12,599
Lower CI 11,362
Bendamustine overall response Base-case Upper CI 11,103
Lower CI 12,950
Chlorambucil complete response/overall response Base-case Upper CI 12,319
Lower CI 11,741
Bendamustine complete response/overall response Base-case Upper CI 11,473
Lower CI 12,454
Re-treatment
Re-treatment algorithm Base-case Bendamustine re-treatment if TTP
24 mo
8,722
First-line efficacy for re-treatment 8,030
Efficacy re-treatment data source Robak et al. [14] Montserrat et al. [24] 11,450
Cutoff duration of response for re-treatment with
chlorambucil
12 mo 6 mo 12,915
24 mo 10,769
Cutoff duration of response for re-treatment with
bendamustine
No re-treatment 6 mo 6,698
12 mo 7,510
FC efficacy
FC data source Robak et al. [15] O’Brien et al. [25] 11,152
Costs
Patient body surface area 1.51–1.75 m2 1.26–1.50 11,412
1.76–2.00 12,492
2.01–2.25 13,041
Health state costs Include Exclude 4,886
20% 13,375
20% 10,545
Costs of FC acquisition and administration Include Exclude 11,812
20% 11,990
20% 11,931
Adverse event costs (bendamustine/chlorambucil) Include Exclude 11,815
20% 11,989
20% 11,931
Utilities
Source Beusterien et al. [16] NICE technology appraisal guidance
119 (fludarabine) [26]*
11,024
NICE technology appraisal guidance
174 (rituximab) [27]†
10,607
Allow response impact on quality of life during treatment No Yes 11,803
Adverse event utilities (bendamustine/chlorambucil) Include Exclude 11,815
20% 11,989
20% 11,931
Decision maker
Discount rate (costs/outcomes) 3.5% 0% 12,256
6% 11,842
Time horizon 35 y Trial duration (68 mo) 8,551
10 y 10,371
20 y 11,755
30 y 11,944
Note. Costs are in sterling.
CI, confidence interval; FC, fludarabine plus cyclophosphamide; ICER, incremental cost-effectiveness ratio; TTP, time to treatment progression.
* Utility of 0.74 for any on-treatment states (no further impact of adverse events modeled), utility of 0.80 for any response states, and utility of
0.60 for any progressed states.
† Utility of 0.80 for first-line preprogression, and utility of 0.60 from first progression until death.
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769V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 7 5 9 – 7 7 0spectively, compared with ITT estimates of 35%, 3%, and 1%. Mod-
eled overall survival for bendamustine at 12, 36, and 54 months
was 97%, 85%, and 71%, respectively, comparedwith ITT estimates
of 92%, 84%, and 70%. Modeled overall survival for chlorambucil at
the same time periods was 94%, 76%, and 57%, respectively, com-
pared with ITT estimates of 92%, 78%, and 55%.
The study by Knauf et al. [6] established progression status
very 3 months; data for this end point are therefore interval
ensored, because we only know the time interval during which
n event occurred, not the exact date of the event. In line with
he clinical analysis, the cost-effectiveness modeling did not
ake account of the interval-censored nature of the data and
nstead used the date of observed progression as the event date.
his approach biases the median PFS upward, although the dif-
erence between treatment groups should not be systematically
iased [34]. Again, it is not expected that this would have sub-
tantively impacted the ICER. Further research to establish the
mpact of interval censoring on cost-effectiveness analysis gen-
rally, however, is warranted.
TheNICE Evidence ReviewGroup report issued during theNICE
ppraisal process described the model as high quality [35]. It dis-
agreed, however, with some assumptions in the model: 1) that
patients in PD have a blood transfusion every 3 weeks (the report
stated that an assumption of a transfusion every 4 weeks in the
last 6 months of life is more appropriate); 2) that the HR for overall
survival is 1.66 (the report stated that the latest data showed this
to be 1.3 [32]). It also disagreed with the assumptions around dose
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Fig 6 – Results of probabilistic sensitivity analysis (5000
simulations). (A) Distributions of simulations on the cost-
effectiveness plane and (B) cost-effectiveness acceptability
curve. QALY, quality-adjusted life-year.intensities and how often patients would visit a hematologistwhile not being treated. Updating themodel by using the Evidence
ReviewGroup’s assumptions gave an alternative base-case ICER of
£9400 per QALY.
Further work could be undertaken to look at the effect of sub-
sequent lines of therapy and cross-over on the overall survival
benefit [36]. This may be of interest because during trial follow-up
patients receiving first-line chlorambucil were more intensively
treated postprogression than those receiving first-line bendamus-
tine. Sixty-three percent of patients who received first-line
chlorambucil received further antineoplastic treatment (and 29%
received bendamustine) compared with 49% of bendamustine pa-
tients (13% were re-treated with bendamustine) [9].
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